NASDAQ:NEXI - NexImmune Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $30.33
  • Forecasted Upside: 282.03 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$7.94
▼ -1.06 (-11.78%)

This chart shows the closing price for NEXI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New NexImmune Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NEXI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NEXI

Analyst Price Target is $30.33
▲ +282.03% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for NexImmune in the last 3 months. The average price target is $30.33, with a high forecast of $35.00 and a low forecast of $21.00. The average price target represents a 282.03% upside from the last price of $7.94.

This chart shows the closing price for NEXI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 polled investment analysts is to buy stock in NexImmune.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/4/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/2/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/1/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/1/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/30/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/28/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/27/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/26/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/15/2021Raymond JamesLower Price TargetOutperform$30.00 ➝ $21.00High
3/31/2021Raymond JamesInitiated CoverageOutperform$30.00High
3/9/2021BarclaysInitiated CoverageOverweight$35.00Low
3/9/2021Cantor FitzgeraldInitiated CoverageOverweight$35.00Low
(Data available from 11/27/2016 forward)

News Sentiment Rating

0.17 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/31/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2021
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/30/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/29/2021
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/28/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/28/2021
  • 2 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
11/27/2021

Current Sentiment

  • 2 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
NexImmune logo
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; and NEXI-002, an autologous cell therapy, which is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
Read More

Today's Range

Now: $7.94
Low: $7.94
High: $9.33

50 Day Range

MA: $13.08
Low: $7.94
High: $16.90

52 Week Range

Now: $7.94
Low: $7.94
High: $28.00

Volume

28,748 shs

Average Volume

72,051 shs

Market Capitalization

$180.33 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of NexImmune?

The following Wall Street analysts have issued reports on NexImmune in the last year: Barclays PLC, Cantor Fitzgerald, Raymond James, and Zacks Investment Research.
View the latest analyst ratings for NEXI.

What is the current price target for NexImmune?

3 Wall Street analysts have set twelve-month price targets for NexImmune in the last year. Their average twelve-month price target is $30.33, suggesting a possible upside of 282.0%. Barclays PLC has the highest price target set, predicting NEXI will reach $35.00 in the next twelve months. Raymond James has the lowest price target set, forecasting a price of $21.00 for NexImmune in the next year.
View the latest price targets for NEXI.

What is the current consensus analyst rating for NexImmune?

NexImmune currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NEXI will outperform the market and that investors should add to their positions of NexImmune.
View the latest ratings for NEXI.

How do I contact NexImmune's investor relations team?

NexImmune's physical mailing address is 9119 GAITHER ROAD, GAITHERSBURG MD, 20877. The company's listed phone number is 301-825-9810 and its investor relations email address is [email protected] The official website for NexImmune is www.neximmune.com.